INTUNIV™ is a once-daily, extended-release formulation of guanfacine hydrochloride (HCl) in a matrix tablet formulation for oral administration only.
INTUNIV™ is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of INTUNIV™ was studied for the treatment of ADHD in two controlled clinical trials (8 and 9 weeks in duration) in children and adolescents ages 6-17 who met DSM-IV® criteria for ADHD [see Clinical Studies ]. The effectiveness of INTUNIV™ for long-term use (more than 9 weeks) has not been systematically evaluated in controlled trials.
A diagnosis of ADHD implies the presence of hyperactive-impulsive and/or inattentive symptoms that cause impairment and were present before the age of 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go"; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.
Media Articles Related to Intuniv (Guanfacine)
Calorie restriction improves sleep apnea, hypertension in obese people
Source: Hypertension News From Medical News Today [2014.09.12]
Restricting calories may improve obstructive sleep apnea and reduce high blood pressure in obese adults, according to a study presented at the American Heart Association's High Blood Pressure...
Hypertension up to Six Times More Likely in Obese vs Slim Youth
Source: theheart.org | Medscape Cardiology Headlines [2014.09.10]
Overweight and obese boys and girls were much more likely to have hypertension than normal-weight children in a new study; thus, weight loss should be encouraged to reduce later CVD risk.
Hypertension is a nearly 6 fold risk factor in obese youths
Source: Hypertension News From Medical News Today [2014.09.03]
Obese youths have a nearly six fold risk of hypertension, according to research in more than 22 000 young people from the PEP Family Heart Study presented at ESC Congress by Professor Peter Schwandt...
Stroke risk increased by resistant hypertension: 35 percent in women and 20 percent in elderly Taiwanese
Source: Hypertension News From Medical News Today [2014.09.03]
Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan.
Potential to treat pulmonary hypertension with protein in 'good cholesterol'
Source: Cholesterol News From Medical News Today [2014.09.01]
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis.
Published Studies Related to Intuniv (Guanfacine)
Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration, guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD (hyperactivity, impulsivity and inattention) in children and adolescents...
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
CONCLUSIONS: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms. Clinical Trial Registration Number: NCT00367835.
Guanfacine extended-release: in attention deficit hyperactivity disorder. 
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an
extended-release (ER) tablet for the treatment of attention deficit hyperactivity
disorder (ADHD) in children and adolescents (aged 6-17 years). In two large,
randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration,
guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD
(hyperactivity, impulsivity and inattention) in children and adolescents...
Effects of extended-release guanfacine on ADHD symptoms and sedation-related
adverse events in children with ADHD. 
CONCLUSION: These results suggest that acclimation to GXR may minimize the risk
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. [2009.02]
CONCLUSIONS:: Guanfacine extended-release was effective in reducing symptoms of ADHD. Adverse events were mild to moderate, did not interfere with improvements in attention, and rarely led to discontinuation.
Clinical Trials Related to Intuniv (Guanfacine)
Guanfacine in Children With Tic Disorders [Recruiting]
The goal of this pilot study is to obtain preliminary information on the tolerability and
efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette
Disorder (TD, also called Tourette syndrome).
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia [Recruiting]
This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if
guanfacine extended release is able to improve nighttime sleep in children with ADHD -
associated insomnia while improving daytime ADHD symptoms. Male and female children with
diagnosed or suspected ADHD with sleep problems (difficulty falling asleep, difficulty
staying asleep, or less than expected hours of sleep) will be recruited. After obtaining
informed consent and assent (when appropriate) and after discontinuation of excluded
medications, children will have evaluations of his or her sleep and evaluations confirming
the ADHD diagnosis. Children who successfully pass screening will be enrolled into the
double-blind, placebo-controlled, randomized investigation with 50% of participants
receiving guanfacine extended release and 50% of participants receiving matching placebo.
Using a flexible-dose optimization design based on ADHD symptom improvement and medication
tolerability, the dose will be adjusted between 1 to 4 mg over the course of four weeks. At
the end of medication adjustment (week 4 or 5), ADHD questionnaires, sleep questionnaires,
and sleep tests will be repeated and analyzed. The medication will be weaned over the course
of the following 3-10 days.
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder [Recruiting]
The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself
or in combination with methylphenidate (also known as Ritalin) is helpful for treating
hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) [Recruiting]
All subjects with the study will be children (age 6-12) with Attention Deficit Hyperactivity
Disorder (ADHD). After baseline assessment confirms the presence of ADHD, children will
have an Event related potential (ERP) (a type of electroencephalogram [EEG]) study. After
the baseline EEG, children will be randomized to either placebo or GXR for a 4-week,
parallel groups trial. During this trial, dosing will be flexibly adjusted according to
patient response or presence of side effects. The dosage will range from 1-4 mg. At the
end of the four week trial, a follow up ERP study will be obtained.
Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD [Recruiting]
This study proposes to evaluate the effects of guanfacine extended release on brain
activation during fMRI in children and adolescents with ADHD between the ages 8-15 and ADHD
subjects randomized to placebo treatment.
This study also proposes to collect DNA on study participants, to examine the genetic
underpinning of the observed fMRI activation profiles at baseline and in response to
treatment. The purpose is to examine polymorphisms of the adrenergic 2A gene (and other
related targets) for genetic biomarkers in association with the fMRI findings of this study.
Reports of Suspected Intuniv (Guanfacine) Side Effects
OFF Label USE (7),
Loss of Consciousness (6),
Inappropriate Schedule of Drug Administration (6),
Convulsion (6), more >>